| Item Type | Name |
|
Academic Article
|
Randomized trial of partial versus complete chordal preservation methods of mitral valve replacement: A preliminary report.
|
|
Academic Article
|
Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function.
|
|
Academic Article
|
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
|
|
Academic Article
|
Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications.
|
|
Academic Article
|
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
|
|
Academic Article
|
The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
|
|
Academic Article
|
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction.
|
|
Academic Article
|
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
|
|
Academic Article
|
Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM).
|
|
Academic Article
|
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
|
|
Academic Article
|
Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial.
|
|
Concept
|
Treatment Outcome
|
|
Academic Article
|
Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.
|
|
Academic Article
|
Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies.
|
|
Academic Article
|
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
|
|
Academic Article
|
Developing therapies for heart failure with preserved ejection fraction: current state and future directions.
|
|
Academic Article
|
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
|
|
Academic Article
|
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
|
|
Academic Article
|
Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
|
|
Academic Article
|
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
|
|
Academic Article
|
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
|
|
Academic Article
|
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
|
|
Academic Article
|
Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
|
|
Academic Article
|
Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
|
|
Academic Article
|
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
|
|
Academic Article
|
Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
|
|
Academic Article
|
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
|
|
Academic Article
|
Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance.
|
|
Academic Article
|
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
|
|
Academic Article
|
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
|
|
Academic Article
|
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
|
|
Academic Article
|
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
|
|
Academic Article
|
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
|
|
Academic Article
|
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
|
|
Academic Article
|
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.
|
|
Academic Article
|
Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial.
|
|
Academic Article
|
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
|
|
Academic Article
|
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
|
|
Academic Article
|
Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
|
|
Academic Article
|
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
|
|
Academic Article
|
Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
|
|
Academic Article
|
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
|
|
Academic Article
|
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
|
|
Academic Article
|
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
|
|
Academic Article
|
Health-Related Quality of Life Outcomes in PARADIGM-HF.
|
|
Academic Article
|
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
|
|
Academic Article
|
Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.
|
|
Academic Article
|
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
|
|
Academic Article
|
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
|
|
Academic Article
|
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
|
|
Academic Article
|
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
|
|
Academic Article
|
Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease.
|
|
Academic Article
|
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).
|
|
Academic Article
|
Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment Concept.
|
|
Academic Article
|
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
|
|
Academic Article
|
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
|
|
Academic Article
|
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.
|
|
Academic Article
|
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
|
|
Academic Article
|
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
|
|
Academic Article
|
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
|
|
Academic Article
|
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
|
|
Academic Article
|
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
|
|
Academic Article
|
Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure.
|
|
Academic Article
|
Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension.
|
|
Academic Article
|
Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE.
|
|
Academic Article
|
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
|
|
Academic Article
|
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
|
|
Academic Article
|
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
|
|
Academic Article
|
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.
|
|
Academic Article
|
Incidence and Outcomes of Pneumonia in Patients With Heart Failure.
|
|
Academic Article
|
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
|
|
Academic Article
|
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF.
|